" class="no-js "lang="en-US"> David Fattal - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
David Fattal

David Fattal

About David Fattal

He is a master manipulator of light at the nanoscale – including single photon guns, quantum teleportation and holographic displays. He has a passion for “making magic” and as Leia’s Chief Innovator, a mission to share it woth the world.

Related Story

Artificial Intelligence

 Leia Inc. Partners With Anatomage to Enable 3D Stereoscopic Learning Through Anatomage VR | Pharmtech Focus

Leia Inc. Partners With Anatomage to Enable 3D Stereoscopic Learning Through Anatomage VR

May 19 2022

Leia Inc., the leading 3D experience platform leveraging proprietary Nanotechnology and AI to democratize the […]